Virtual Investor Event
Join Hansa Biopharma for an investor event featuring two KOLs discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).
June 16, 14:00 CEST/8:00 AM ET
Register and attend
We are on a mission is to deliver innovation to people living with immune-mediated diseases
Chairman's letter
"In my third year as Chairman of the Board of Directors, I’m excited for what’s to come. Hansa remains on track to advance innovative science and deliver important new medicines to the patients who need it most."
Peter Nicklin
Chair of the Board, Hansa Biopharma
CEO statement
"2024 was a momentum-building year for Hansa that has positioned us well to advance our efforts in Autoimmune, Gene Therapy and Transplantation."
Søren Tulstrup
President and CEO, Hansa Biopharma
Hansa’s mission is to leverage our unique immunomodulating technology platform to develop innovative, lifesaving and life altering treatments for people with rare immunological conditions, ensure fair and equitable access to these medicines, and generate value to society at large.
Successfully launch IDEFIRIX® in Europe
Secure FDA approval and launch in the U.S.
Geographic expansion
Achieve approval/usage of imlifidase in follow-on indications
Broaden the IDEFIRIX® label beyond kidney transplantation into areas of high unmet need in Autoimmunity and Gene Therapy
Advance HNSA-5487, the Company’s next generation IgG-cleaving enzyme with redosing potential, into neuroautoimmunity including myasthenia gravis (MG)
Market Access secured in the five largest European markets and in a total of 18 European markets.
Record full year sales of 189.7 MSEK
Record quarterly sales of 69.5 MSEK in the third quarter of 2024
Sarepta initiated a Phase 1b clinical trial (SRP-9001-104) evaluating the use of imlifidase as pre-treatment ahead of Sarepta’s gene therapy in DMD.
Genethon initiated a Phase 2 clinical trial (GNT-018IDES) evaluating the efficacy and safety Genethon’s gene therapy GNT-0003 following pre-treatment with imlifidase in patients with severe Crigler-Najjar syndrome.
Full results of the NICE-01 first in human trial and 12-month follow up analysis of HNSA-5487, the Company’s next generation IgGcleaving molecule with redosing potential.
Completed randomization of Hansa’s pivotal Phase 3 trial (ConfIdeS), evaluating imlifidase as potential desensitization therapy to enable kidney transplantation in highly sensitized patients.
Positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase in GBS and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain Barré Syndrome Outcome Study (IGOS).
Completion of enrolment of the GOOD-IDES-02 Phase 3 trial in anti-GBM disease.
SEK ~372m (USD ~34.6m) raised in a directed share issue in April 2024.
Cash runway into 2026.
New International guidelines published in Transplant International on appropriate use of imlifidase in clinical practice to enable kidney transplants in highly sensitized patients.
In 2024, 53 patients eligible for IDEFIRIX® were identified by transplant centers in countries participating in Eurotransplant’s Desensitization Program.
Real-world evidence on use of imlifidase in highly sensitized kidney transplant published in Kidney International Reports in July 2024 and presented at the American Society of Transplantation’s annual congress in June 2024.
Awarded Great Place to Work in 2024 (for the fifth consecutive year) by the independent institute Great Place to Work®.
Hansa is developing novel immunomodulating biologic therapies based on a proprietary, first-in-class IgG cleaving platform.
Autoimmune diseases have a significant impact on the individuals and families they affect. As their frequency and prevalence grow and more autoimmune diseases are identified, they impact the life of a growing proportion of the population, with associated growing costs for healthcare systems.
Our first-generation IgG immunoglobulin G (IgG) antibody cleaving enzyme, could potentially address IgG-driven autoimmune diseases and conditions, while our next-generation enzyme with its redosing potential could play an important role in autoimmune diseases where there is a need for better management of initial and repeat immune system attacks.
For people living with one of the approximately 7,000 known rare, monogenic diseases, gene therapies may offer a cure to a life-long condition by introducing genetic material that compensates for a defective gene. However, if the therapy is based on the use of Adeno Associated Virus (AAV) vectors, the immune system may carry antibodies that counteract the gene therapy treatment preventing its success.
We partner closely with cutting edge gene therapy companies to advance the scientific understanding of how Hansa’s proprietary IgG-cleaving technology may have the potential to help overcome the immunological barrier to treatment created by anti-AAV antibodies, and enable these potentially life-saving treatments for more patients.
End stage renal disease (ESRD) or kidney failure is a serious, progressive, often-times fatal disease, affecting nearly 2.5 million patients worldwide. Receiving a transplant is life-changing, and the treatment of choice for ESRD. Among the people waiting for a donor kidney, those considered highly sensitized face unique challenges that can result in inequitable access to donor organs and transplantation and extended time on dialysis.
Hansa continues to advance the science around desensitization to help ensure equitable access to care for highly sensitized kidney transplant patients.
“With a keen eye towards becoming a more sustainable, ethical and transparent organization, Hansa has the opportunity to deliver innovative new medicines to people in areas with high unmet need.”
Søren Tulstrup
President and CEO, Hansa Biopharma
Our sustainability strategy ensures we are addressing the most relevant topics to our business and meet the expectations of external and internal stakeholders. We aim to act as a responsible business that plays an important role in society and strives to have a positive impact on the communities where we operate.
1. Addressing unmet medical needs
2. Cultivating an engaged culture by fostering inclusivity, collaboration, and innovation
3. Embracing sustainable decision-making and environmental stewardship
4. Making a difference by operating an ethical, transparent,
and responsible business
At Hansa, we have identified where we can positively contribute to the United Nations’ Sustainable Development Goals.
Different nationalities
Renewable electricity used
Women among employees
Completion rate Great Place To Work Survey